logo
Plus   Neg
Share
Email

Lilly : CHMP Issues Positive Opinion To Expand Trulicity Label

Eli Lilly and Co. (LLY) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP issued a positive opinion recommending an update to the Trulicity or dulaglutide label and indication statement.

The committee agreed the label should include results from the REWIND cardiovascular outcomes trial, which achieved a significant 12 percent risk reduction in major adverse cardiovascular events or MACE.

The CHMP has recommended updating the Trulicity indication to reflect both glycemic control and the impact on cardiovascular events as fundamental considerations in a treatment for people with type 2 diabetes.

In addition, the updated label will reflect the consistent MACE risk reduction with Trulicity across major demographic and disease subgroups.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has removed four separate networks of accounts, pages and groups for engaging in co-ordinated inauthentic behavior on Facebook and Instagram. These networks originated from Iran and Russia and primarily targeted the US, North Africa and Latin America. These networks often posted on both sides of political issues including topics like US elections, environmental issues, racial tensions. While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020.
Follow RTT
>